115 related articles for article (PubMed ID: 37309095)
1. Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin.
Cao C; Pei Y; Yu H; Qi H
J Chemother; 2024 Apr; 36(2):156-166. PubMed ID: 37309095
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.
Baranski Z; de Jong Y; Ilkova T; Peterse EF; Cleton-Jansen AM; van de Water B; Hogendoorn PC; Bovée JV; Danen EH
Oncotarget; 2015 Nov; 6(34):36113-25. PubMed ID: 26416351
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031
[TBL] [Abstract][Full Text] [Related]
4. Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins.
Gonçalves C; Martins-Neves SR; Paiva-Oliveira D; Oliveira VE; Fontes-Ribeiro C; Gomes CM
Life Sci; 2015 Jun; 130():47-56. PubMed ID: 25818183
[TBL] [Abstract][Full Text] [Related]
5. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
6. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
7. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
Ryu K; Susa M; Choy E; Yang C; Hornicek FJ; Mankin HJ; Duan Z
BMC Cancer; 2010 May; 10():187. PubMed ID: 20459702
[TBL] [Abstract][Full Text] [Related]
8. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing.
Zhao Y; Zhang CL; Zeng BF; Wu XS; Gao TT; Oda Y
Biochem Biophys Res Commun; 2009 Dec; 390(3):642-7. PubMed ID: 19818735
[TBL] [Abstract][Full Text] [Related]
9. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Shi J; Zhou Y; Huang HC; Mitchison TJ
Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
[TBL] [Abstract][Full Text] [Related]
10. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
13. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
14. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
16. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
17. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
18. A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.
Manzella G; Moonamale DC; Römmele M; Bode P; Wachtel M; Schäfer BW
Neoplasia; 2021 Sep; 23(9):929-938. PubMed ID: 34329950
[TBL] [Abstract][Full Text] [Related]
19. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.
Yang MC; Lin RW; Huang SB; Huang SY; Chen WJ; Wang S; Hong YR; Wang C
Cell Cycle; 2016; 15(3):394-402. PubMed ID: 26694174
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
Jin J; Xiong Y; Cen B
Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
